212 related articles for article (PubMed ID: 9218165)
1. Amisulpride: from animal pharmacology to therapeutic action.
Scatton B; Claustre Y; Cudennec A; Oblin A; Perrault G; Sanger DJ; Schoemaker H
Int Clin Psychopharmacol; 1997 May; 12 Suppl 2():S29-36. PubMed ID: 9218165
[TBL] [Abstract][Full Text] [Related]
2. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
[TBL] [Abstract][Full Text] [Related]
3. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
Schoemaker H; Claustre Y; Fage D; Rouquier L; Chergui K; Curet O; Oblin A; Gonon F; Carter C; Benavides J; Scatton B
J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185
[TBL] [Abstract][Full Text] [Related]
4. [The place of amisulpride in the atypical neuroleptic class].
Perrault G; Schoemaker H; Scatton B
Encephale; 1996 Jun; 22 Spec No 2():3-8. PubMed ID: 8767034
[TBL] [Abstract][Full Text] [Related]
5. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS
Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
[TBL] [Abstract][Full Text] [Related]
6. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
Leucht S
Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080
[TBL] [Abstract][Full Text] [Related]
7. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia.
Xiberas X; Martinot JL; Mallet L; Artiges E; Canal M; Loc'h C; Mazière B; Paillère-Martinot ML
J Clin Psychopharmacol; 2001 Apr; 21(2):207-14. PubMed ID: 11270918
[TBL] [Abstract][Full Text] [Related]
8. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality.
Möller HJ
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1101-11. PubMed ID: 14642970
[TBL] [Abstract][Full Text] [Related]
9. Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine.
Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
Schizophr Res; 2008 Oct; 105(1-3):224-35. PubMed ID: 18710798
[TBL] [Abstract][Full Text] [Related]
10. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients.
Bressan RA; Erlandsson K; Spencer EP; Ell PJ; Pilowsky LS
Psychopharmacology (Berl); 2004 Sep; 175(3):367-73. PubMed ID: 14997280
[TBL] [Abstract][Full Text] [Related]
11. Effects of amisulpride, an atypical antipsychotic which blocks preferentially presynaptic dopamine autoreceptors, on integrated functional cerebral activity in the rat.
Cudennec A; Fage D; Bénavidès J; Scatton B
Brain Res; 1997 Sep; 768(1-2):257-65. PubMed ID: 9369323
[TBL] [Abstract][Full Text] [Related]
12. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15.
Kiss B; Laszlovszky I; Horváth A; Némethy Z; Schmidt E; Bugovics G; Fazekas K; Gyertyán I; Agai-Csongor E; Domány G; Szombathelyi Z
Naunyn Schmiedebergs Arch Pharmacol; 2008 Nov; 378(5):515-28. PubMed ID: 18551280
[TBL] [Abstract][Full Text] [Related]
13. Is amisulpride an 'atypical' atypical antipsychotic agent?
Lecrubier Y
Int Clin Psychopharmacol; 2000 Dec; 15 Suppl 4():S21-6. PubMed ID: 11252520
[TBL] [Abstract][Full Text] [Related]
14. Amisulpride: a review of its use in the management of schizophrenia.
Curran MP; Perry CM
Drugs; 2001; 61(14):2123-50. PubMed ID: 11735643
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of dopamine research in schizophrenia.
Pani L
Curr Med Res Opin; 2002; 18 Suppl 3():s3-7. PubMed ID: 12418605
[TBL] [Abstract][Full Text] [Related]
16. Consensus on the use of substituted benzamides in psychiatric patients.
Racagni G; Canonico PL; Ravizza L; Pani L; Amore M
Neuropsychobiology; 2004; 50(2):134-43. PubMed ID: 15292667
[TBL] [Abstract][Full Text] [Related]
17. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15.
Gyertyán I; Sághy K; Laszy J; Elekes O; Kedves R; Gémesi LI; Pásztor G; Zájer-Balázs M; Kapás M; Agai Csongor E; Domány G; Kiss B; Szombathelyi Z
Naunyn Schmiedebergs Arch Pharmacol; 2008 Nov; 378(5):529-39. PubMed ID: 18548231
[TBL] [Abstract][Full Text] [Related]
18. From pharmacological profiles to clinical outcomes.
Kerwin R
Int Clin Psychopharmacol; 2000 Dec; 15 Suppl 4():S1-4. PubMed ID: 11252517
[TBL] [Abstract][Full Text] [Related]
19. Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study.
Meisenzahl EM; Schmitt G; Gründer G; Dresel S; Frodl T; la Fougère C; Scheuerecker J; Schwarz M; Boerner R; Stauss J; Hahn K; Möller HJ
Pharmacopsychiatry; 2008 Sep; 41(5):169-75. PubMed ID: 18763218
[TBL] [Abstract][Full Text] [Related]
20. Evidence for a functional role of the dopamine D3 receptors in the cerebellum.
Barik S; de Beaurepaire R
Brain Res; 1996 Oct; 737(1-2):347-50. PubMed ID: 8930390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
